Correction

Kerr, Lucille; Cadegiani, Flavio; Baldi, Fernando; Lôbo, Raysildo Barbosa; Assagra, Washington Luiz O; Proença, Fernando Carlos; Kory, Pierre; Scheim, David; Chamie-Quintero, Juan

doi:10.7759/cureus.c61

Cited by 7 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Depending on the calculation methods performed for infection rates, this could create some differences. Imprecisions and modifications evident, although minimal, between the first manuscript [ 25 ] and this study, did not impact the fact that ivermectin use reduced COVID-19-related outcomes. In addition, in the present analysis, we did not control for the COVID-19 infection dates.…”

Section: Discussionmentioning

confidence: 61%

“…In our first paper [ 25 ], ivermectin was shown to be associated with significant reductions in infection rate (44%), hospitalization rate (56%), and mortality rate (68%), when compared to subjects that did not use ivermectin prophylactically and irrespective of the regularity of ivermectin use.…”

Section: Discussionmentioning

confidence: 99%

“…A thorough description of the program, study population, and protocol was described elsewhere [ 25 ]. This was a medically based, observational, and prospective study that involved the voluntary use of ivermectin as prophylaxis for COVID-19 in the city of Itajaí, Santa Catarina, Brazil.…”

Section: Methodsmentioning

confidence: 99%

“…While ivermectin non-users remained unchanged from the first analysis [ 25 ], ivermectin users were divided according to the accumulated dose of ivermectin taken.…”

Section: Methodsmentioning

confidence: 99%

“…The systematically collected data within this program demonstrated that ivermectin used as prophylaxis for COVID-19 improved COVID-19 related-outcomes. The use of ivermectin led to a 44% reduction in infection rate, a 56% reduction in hospitalization rate, and a 68% reduction in mortality rate by using propensity score matching (PSM) to balance the study groups [ 25 ].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects

Kerr¹,

Baldi²,

Lôbo³

et al. 2022

Cureus

Self Cite

View full text Add to dashboard Cite

BackgroundWe have previously demonstrated that ivermectin used as prophylaxis for coronavirus disease 2019 , irrespective of the regularity, in a strictly controlled citywide program in Southern Brazil (Itajaí, Brazil), was associated with reductions in COVID-19 infection, hospitalization, and mortality rates. In this study, our objective was to determine if the regular use of ivermectin impacted the level of protection from COVID-19 and related outcomes, reinforcing the efficacy of ivermectin through the demonstration of a doseresponse effect. MethodsThis exploratory analysis of a prospective observational study involved a program that used ivermectin at a dose of 0.2 mg/kg/day for two consecutive days, every 15 days, for 150 days. Regularity definitions were as follows: regular users had 180 mg or more of ivermectin and irregular users had up to 60 mg, in total, throughout the program. Comparisons were made between non-users (subjects who did not use ivermectin), and regular and irregular users after multivariate adjustments. The full city database was used to calculate and compare COVID-19 infection and the risk of dying from COVID-19. The COVID-19 database was used and propensity score matching (PSM) was employed for hospitalization and mortality rates. Results

show abstract

Section: Discussionmentioning

confidence: 61%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

“…While ivermectin non-users remained unchanged from the first analysis [ 25 ], ivermectin users were divided according to the accumulated dose of ivermectin taken.…”

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects

Kerr¹,

Baldi²,

Lôbo³

et al. 2022

Cureus

Self Cite

View full text Add to dashboard Cite

show abstract

Ivermectin's Role in the Prevention of COVID‐19: A Systematic Review and Meta‐Analysis

Liang

Lin

et al. 2022

The Journal of Clinical Pharma

View full text Add to dashboard Cite

This systematic review was performed to determine the population that benefited from prophylactic ivermectin. Seven databases of health-related studies were searched for eligible trials without language restrictions. Randomized controlled trials (RCTs) and cohort studies investigating ivermectin for coronavirus disease 2019 (COVID-19) prevention were included. Data were pooled using a random-effects model, and subgroups were analyzed by study type and the pre-or postexposure population. The certainty of the evidence was determined by the Grading of Recommendations Assessment, Development, and Evaluation approach. Furthermore, 4 RCTs and 4 cohort studies with a moderate to high risk of bias were included in the analysis. The prophylactic use of ivermectin significantly decreased the overall incidence of COVID-19 (odds ratio [OR], 0.26; 95% confidence interval [CI], 0.16-0.44). Nevertheless, the positive result was not supported by the RCT. Ivermectin was associated with a lower risk of COVID-19 (OR, 0.22; 95% CI, 0.12-0.40) in the preexposure population, whereas no protective effect was observed in the postexposure population (OR, 0.39; 95% CI, 0.09-1.67). In summary, prophylactic ivermectin did not prevent COVID-19 in the postexposure population. Although the protective effect of ivermectin was shown in the overall and preexposure populations, the results were unreliable owing to poor-quality evidence.

show abstract

Results of a systematic review and meta-analysis of early studies on ivermectin in SARS-CoV-2 infection

et al. 2023

View full text Add to dashboard Cite

Ivermectin, an antiparasitic drug, has been repurposed for COVID-19 treatment during the SARS-CoV-2 pandemic. Although its antiviral efficacy was confirmed early in vitro and in preclinical studies, its clinical efficacy remained ambiguous. Our purpose was to assess the efficacy of ivermectin in terms of time to viral clearance based on the meta-analysis of available clinical trials at the closing date of the data search period, one year after the start of the pandemic. This meta-analysis was reported by following the PRISMA guidelines and by using the PICO format for formulating the question. The study protocol was registered on PROSPERO. Embase, MEDLINE (via PubMed), Cochrane Central Register of Controlled Trials (CENTRAL), bioRvix, and medRvix were searched for human studies of patients receiving ivermectin therapy with control groups. No language or publication status restrictions were applied. The search ended on 1/31/2021 exactly one year after WHO declared the public health emergency on novel coronavirus. The meta-analysis of three trials involving 382 patients revealed that the mean time to viral clearance was 5.74 days shorter in case of ivermectin treatment compared to the control groups [WMD = −5.74, 95% CI (−11.1, −0.39), p = 0.036]. Ivermectin has significantly reduced the time to viral clearance in mild to moderate COVID-19 diseases compared to control groups. However, more eligible studies are needed for analysis to increase the quality of evidence of ivermectin use in COVID-19.

show abstract

Correction

Cited by 7 publications

References 0 publications

Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects

Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects

Ivermectin's Role in the Prevention of COVID‐19: A Systematic Review and Meta‐Analysis

Results of a systematic review and meta-analysis of early studies on ivermectin in SARS-CoV-2 infection

Contact Info

Product

Resources

About